Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 270-275

  Ng, A K ^a,d   Li, S ^b   Neuberg, D ^b   Silver, B ^a   Stevenson, M A ^c   Fisher, D C ^b   Mauch, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Chemotherapy; Hodgkin's disease; Radiation therapy; Relapse; Salvage therapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; AGE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; INFERTILITY; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; VINBLASTINE; VINCRISTINE;

EID: 1342288897     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh067     Document Type: Article

References (29)

1. Olver IN, Wolf MM, Cruickshank D et al. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. Cancer 1988; 62: 233-239.
2. Roach M 3rd, Brophy N, Cox R et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623-629.
3. Hoppe RT. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A: 1920-1922.
4. Healey EA, Tarbell NJ, Kalish LA et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71: 2613-2620.
5. Specht L, Horwich A, Ashley S. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994;30:805-811.
6. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33: 848-853.
7. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96: 139-143.
8. Piga A, Ambrosetti A, Todeschini G et al. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treat Rep 1984; 68: 947-951.
9. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
10. Carde P, Hagenbeek A, Hayat M et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-2272.
11. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 1978; 42: 1039-1045.
12. Prosnitz LR, Curtis AM, Knowlton AH et al. Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 1980; 6: 809-813.
13. Lee CK, Bloomfield CD, Goldman AI et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 1980; 46: 2403-2409.
14. Bosi A, Ponticelli P, Casini C et al. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Haematologica 1989; 74: 463-473.
15. Diaz-Pavon JR, Cabanillas F, Majlis A et al. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol 1995; 13: 19-27.
16. Weekes CD, Vose JM, Lynch JC et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087-1093.
17. Kim HK, Silver B, Li S et al. Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 2003; 56: 556-560.
18. Santoro A, Viviani S, Villarreal CJ et al. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70: 343-348.
19. Noordijk E, Carde P, Hagenbeek A et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF', 'H7-F' and 'H7-U. Proceedings of the Thirty-ninth Annual ASTRO Meeting, Orlando, FL 1997. 39 (suppl 2): 173.
20. Hoppe RT, Coleman CN, Cox RS et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59: 455-465.
21. Noordijk EM, Carde P, Mandard AM et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994; 5: 107-112.
22. Specht L, Gray RG, Clarke MJ et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830-843.
23. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-4244.
24. Valagussa P, Santoro A, Fossati-Bellani F et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830-837.
25. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7-13.
26. Andrieu J, Ifrah N, Payen C et al. Increased risk of secondary acute non-lymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8: 1148-1154.
27. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063-1073.
28. Viviani S, Santoro A, Ragni G et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21: 601-605.
29. Bokemeyer C, Schmoll HJ, van Rhee J et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994; 68: 105-110.